Philips Abdominal Aortic Aneruysm (AAA) Model Provides Physicians a More Patient Friendly Solution Compared to the Current Standard of Care for Managing AAA Patients

January 27, 2021

Philips Abdominal Aortic Aneurysm (AAA) Model is based on 3D ultrasound, Philips AAA Model delivers clinicians accurate diagnostic information without exposing patients to high doses of radiation and nephrotoxic contrast agents.

An abdominal aortic aneurysm (AAA) is an aneurysm that forms in the lower part of the aorta. Typically, AAAs are identified incidentally during abdominal imaging exams but, in some cases, remain undetected until rupture. A ruptured AAA has an 80% mortality rate [1], emphasizing the importance of routine surveillance. Philips AAA Model integrates innovative software and leading Philips 3D ultrasound technologies into a single solution to help increase diagnostic confidence and an improved patient experience. The software automatically segments and quantifies the size of the aneurysm sac for surveillance of known native (untreated), and post-EVAR (treated) AAAs.

The current standard of care for AAAs includes 2D ultrasound and computed tomography angiography (CTA). Each of these modalities has its drawbacks, including inter-operator variability with 2D ultrasound and patient exposure to high levels of radiation and nephrotoxic contrast agents with CTA.

A recent clinical study showed that 3D ultrasound examination for native AAA surveillance has excellent inter-operator reproducibility, superior to that of 2D ultrasound, supporting the broader use of 3D ultrasound in standard AAA surveillance programs [2]. 3D ultrasound has been shown to estimate the diameter and volume of an AAA with acceptable reproducibility and an improved agreement (over 2D ultrasound) with CT [3]. Furthermore, 3D ultrasound has also been proven to correlate significantly better to 3D CT than 2D ultrasound for assessing the maximum diameter of the residual sac post-EVAR, with clinically acceptable reproducibility [4].

“Regular surveillance of abdominal aortic aneurysm patients is essential, but today’s standard of care has downsides,” said Bich Le, Senior Vice President, General Manager Ultrasound at Philips. “Philips Abdominal Aortic Aneurysm (AAA) Model seamlessly integrates leading Philips technologies including Philips Premium Ultrasound System (EPIQ Elite), Philips Array Transducer (X6-1 xMATRIX) and innovative software into a single solution, to help improve the experience and outcomes for clinicians and patients alike.”

Note: Philips will debut the AAA Model at the LINC (Leipzig Interventional Course) Summit, Europe’s premiere interventional course for vascular specialists, taking place virtually, Jan. 25-29, 2021.

The Philips Abdominal Aortic Aneurysm (AAA) Model is CE marked for sale in Europe and is FDA cleared for sale in the U.S.

[1] Age-specific incidence, risk factors, and outcome of acute abdominal aortic aneurysms in a defined population. Howard DP, Banerjee A, Fairhead JF, et al. Br J Surg. 2015;102(8):907–915. doi:10.1002/bjs.9838
[2] Clinical validation of three-dimensional ultrasound for abdominal aortic aneurysm. Ghulam, Qasam M. et al., Journal of Vascular Surgery, Volume 71, Issue 1
[3] Three-dimensional ultrasound evaluation of small asymptomatic abdominal aortic aneurysms. Bredahl, K. et al. European Journal of Vascular and Endovascular Surgery, Volume 49, Issue 3, 289 – 296
[4] Three-dimensional ultrasound improves the accuracy of diameter measurement of the residual sac in EVAR patients. K. Bredahl, M. Taudorf, A. Long, L. Lönn, L. Rouet, R. Ardon, H. Sillesen, J.P. Eiberg. European Journal of Vascular and Endovascular Surgery, Volume 46, Issue 5, 2013


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy